Rate of D‐alloimmunization in trauma does not depend on the number of RhD‐positive units transfused: The BEST collaborative study. (24th June 2022)

• Record Type: Journal Article
• Authors: Seheult, Jansen N.; Callum, Jeannie; Delaney, Meghan; Drake, Rosanna; Dunbar, Nancy M.; Harm, Sarah K.; Hess, John R.; Jackson, Bryon P.; Javanbakht, Ayda; Moore, Sarah A.; Murphy, Michael F.; Raval, Jay S.; Staves, Julie; Tuott, Erin E.; Wendel, Silvano; Ziman, Alyssa; Yazer, Mark H.
• Other Names: Yazer Mark H. guestEditor.; Watts Sarah A. guestEditor.; Woolley Col Tom guestEditor.
• Is Part Of: Transfusion. Volume 62(2022)Supplement 1
• Page Start: S185
• Page End: S192
• Publication Date: 2022-06-24
• Subjects: alloimmunization -- anti‐D -- rate -- red blood cell -- RhD -- transfusion -- trauma -- whole blood; Hematology -- Periodicals; Blood -- Transfusion -- Periodicals; Blood Group Antigens -- Periodicals; Blood Preservation -- Periodicals; Blood Transfusion -- Periodicals; 615
• DOI: 10.1111/trf.16952
• Languages: English
• ISSNs: 0041-1132

Abstract

Abstract: Background: Evidence indicates the life‐saving benefits of early blood product transfusion in severe trauma resuscitation. Many of these products will be RhD‐positive, so understanding the D‐alloimmunization rate is important. Methods: This was a multicenter, retrospective study whereby injured RhD‐negative patients between 18–50 years of age who received at least one unit of RhD‐positive red blood cells (RBC) or low titer group O whole blood (LTOWB) during their resuscitation between 1 January, 2010 through 31 December, 2019 were identified. If an antibody detection test was performed ≥14 days after the index RhD‐positive transfusion then basic demographic information was collected, including whether the patient became D‐alloimmunized. The overall D‐alloimmunization rate, and the rate stratified by the number of units transfused, were calculated. Results: Data were collected from nine institutions. Five institutions reported fewer than 10 eligible patients each and were excluded. From the remaining four institutions, all from the USA, there were 235 eligible patients; 77 (random effects estimate: 32.7%; 95% CI: 19.1–50.1%) became D‐alloimmunized. Three of the institutions reported D‐alloimmunization rates ≥38.6%, while the remaining institution's rate was 12.2%. In both random and fixed‐effects models, the rate of D‐alloimmunization was not significantly different between those who received one RhD‐positive unit and those who received multiple RhD‐positive units. Conclusion: In this large, multicenter study of injured patients, the overall rate of D‐alloimmunization fell within the range previously reported. The rate of D‐alloimmunization did not increase as the number of transfused RhD‐positive units increased. These data can help to inform RhD type selection decisions.